Reflections on a 10-Year Journey in the Microbiome
Following a fortuitous path, researcher Aaron Cowley established expertise in process development for live biotherapeutic products at his company Captozyme. Today, as part of CDMO Arranta Bio, he is looking forward to helping drug developers bring the first microbiome-based therapies to the market. Dr. Aaron B. Cowley is the chief scientific officer at Arranta Bio, […]
Arranta Bio Announces Key Leadership Additions As It Commits to a $100M Investment in Building End-to-End Microbiome Capacity
Arranta Bio, the leading microbiome contract development and manufacturing organization (CDMO), announced the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity as the first dedicated microbiome CDMO. Arranta Bio […]
Oxidien Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an unmet kidney disease indication, announced that it will present at Biotech Showcase™ 2020, to be held January 13–15 at the Hilton San Francisco Union Square, in parallel with the 38th annual J.P. Morgan Healthcare Conference. […]
Oxidien Pharmaceuticals Announces Favorable Response from FDA on Proposed Development Plan
UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for secondary hyperoxaluria, announced that it has received encouraging responses from the U.S. Food and Drug Administration (FDA) regarding their proposed Phase 1/2 trial in secondary hyperoxaluria patients and other development plans for its lead drug candidate. […]